WallStSmart

Churchill Capital Corp XI (CCXI)vsLegato Merger Corp. III (LEGT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

LEGT leads profitability with a 0.0% profit margin vs 0.0%. LEGT earns a higher WallStSmart Score of 28/100 (F).

CCXI

Avoid

24

out of 100

Grade: F

Growth: 4.3Profit: 4.0Value: 5.0Quality: 6.0
Piotroski: 2/9

LEGT

Avoid

28

out of 100

Grade: F

Growth: 3.7Profit: 3.5Value: 4.7Quality: 4.8
Piotroski: 2/9

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCXI0 strengths · Avg: 0/10

No standout strengths identified

LEGT0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

CCXI4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$677.31M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
4.7%3/10

ROE of 4.7% — below average capital efficiency

LEGT4 concerns · Avg: 3.5/10
P/E RatioValuation
36.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

Market CapQuality
$239.65M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : CCXI

CCXI has a balanced fundamental profile.

Bull Case : LEGT

LEGT has a balanced fundamental profile.

Bear Case : CCXI

The primary concerns for CCXI are Revenue Growth, EPS Growth, Market Cap.

Bear Case : LEGT

The primary concerns for LEGT are P/E Ratio, Revenue Growth, Market Cap.

Key Dynamics to Monitor

LEGT is growing revenue faster at 0.0% — sustainability is the question.

LEGT generates stronger free cash flow (-320,535), providing more financial flexibility.

Monitor SHELL COMPANIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

LEGT scores higher overall (28/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Churchill Capital Corp XI

FINANCIAL SERVICES · SHELL COMPANIES · USA

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new drugs for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company is headquartered in Mountain View, California.

Legato Merger Corp. III

FINANCIAL SERVICES · SHELL COMPANIES · USA

Legato Merger Corp. III is a specialized publicly traded acquisition vehicle that targets high-potential businesses across dynamic sectors, aiming to effect transformative mergers that unlock significant shareholder value. With a management team seasoned in identifying and executing strategic transactions, the company focuses on industries ripe for operational enhancements and growth. As investor appetite for innovative investment solutions expands, Legato is well-positioned to leverage market opportunities that not only promise substantial returns but also contribute to the evolution of the sectors in which it invests.

Want to dig deeper into these stocks?